Technical Analysis for ARGSQ - Argos Therapeutics

Grade Last Price % Change Price Change
grade B 0.079 12.86% 0.0090
ARGSQ closed up 12.86 percent on Thursday, May 23, 2019, on 2 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical ARGSQ trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Fell Below 50 DMA Bearish 12.86%
20 DMA Support Bullish 12.86%
Wide Bands Range Expansion 12.86%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%

Older signals for ARGSQ ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. As of February 13, 2019, Argos Therapeutics Inc. operates as a subsidiary of Genexine Inc. and SCM Lifescience Co.
Cancer Infectious Diseases Treatment Of Cancer Cancer Immunotherapy Immunotherapies Ags 004 Arcelis Immunotherapies Based On Its Proprietary Technology Metastatic Renal Cell Carcinoma
Is ARGSQ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.1045
52 Week Low 0.019
Average Volume 12,261
200-Day Moving Average 0.0
50-Day Moving Average 0.0774
20-Day Moving Average 0.0695
10-Day Moving Average 0.0655
Average True Range 0.0163
ADX 47.67
+DI 21.416
-DI 9.0589
Chandelier Exit (Long, 3 ATRs ) 0.03510000000000001
Chandelier Exit (Short, 3 ATRs ) 0.0905
Upper Bollinger Band 0.086
Lower Bollinger Band 0.053
Percent B (%b) 0.79
BandWidth 47.482014
MACD Line -0.0022
MACD Signal Line -0.0036
MACD Histogram 0.0014
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1120
Resistance 3 (R3) 0.1083 0.0937 0.1065
Resistance 2 (R2) 0.0937 0.0853 0.0955 0.1047
Resistance 1 (R1) 0.0863 0.0801 0.0900 0.0900 0.1028
Pivot Point 0.0717 0.0717 0.0735 0.0735 0.0717
Support 1 (S1) 0.0643 0.0633 0.0680 0.0680 0.0552
Support 2 (S2) 0.0497 0.0581 0.0515 0.0533
Support 3 (S3) 0.0423 0.0497 0.0515
Support 4 (S4) 0.0460